Vivos Therapeutics

Name

Vivos Therapeutics

Legal name

Vivos Therapeutics, Inc.

Website

https://vivos.com/

Company type

Public

Founded year

2013

Operating status

Operating

Headcount range

51–100 employees

Ownership category

akta.pro rank

Product category

Sleep Apnea Medical Devices and Treatment Services

SIC

Surgical & Medical Instruments & Apparatus (3841), Services-Health Services (8000), Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro primary industry

Sleep Apnea Therapy Devices (CPAP/APAP/BiPAP/ASV) (HLAHAGAA)

akta.pro secondary industries

Sleep Diagnostics & Monitoring (PSG/Home Sleep Testing, Actigraphy) (HLAHAGAB), Sleep Medicine Clinic (HLAKANAB), Pediatric Dental Sleep Medicine (Airway/SDB Appliances) (HLABAGAJ)

Keywords

• Obstructive sleep apnea treatment
• Oral medical devices
• Sleep medicine services
• Airway rehabilitation appliances
• Pediatric sleep apnea care

Headquarters

HQ city

Littleton

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain, Infrastructure

Revenue model

1. Oral Appliance Sales: Sale of FDA-cleared Vivos CARE oral appliances (DNA, mRNA, mmRNA) to patients through trained dental and medical providers. Revenue recognized from appliance manufacturing, customization, and distribution.
2. Sleep Diagnostic Services: Revenue from sleep testing and diagnosis services through The Sleep Center of Nevada and affiliated sleep centers. Includes overnight polysomnogram (PSG) testing and consultation for OSA, insomnia, and restless leg syndrome. SCN handles approximately 3,000 new patients monthly.
3. Treatment Center Operations: Revenue generated from operating sleep treatment centers, including treatment delivery and follow-up care services. New revenue stream arising from Vivos' operation of acquired sleep centers like SCN.
4. Insurance and Medicare Reimbursements: Revenue from in-network insurance agreements with Medicare, TRICARE, UnitedHealthcare, Anthem, Aetna, Cigna, and Humana covering Vivos appliances and treatment services in Nevada markets.
5. SoundHealth Product Resale: Revenue from resale of SoundHealth's FDA-cleared Sonu Band and Spatial Sleep Band products through Vivos' network of over 2,000 trained providers.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels6 records

Core offering

Vivos Therapeutics develops, manufactures, and distributes FDA 510(k)-cleared oral medical devices (Vivos CARE family: DNA, mRNA, and mmRNA appliances) for the treatment of obstructive sleep apnea (OSA) in adults and children ages 6-17. The company also operates sleep diagnostic and treatment services through acquired and affiliated sleep centers (most notably The Sleep Center of Nevada), provides home sleep testing (VivoScore), and offers complementary products such as the SoundHealth Sonu Band and Spatial Sleep Band wearables through its provider network.

Product overview

Vivos Therapeutics operates as a medical technology and healthcare services company offering a platform of FDA-cleared oral medical devices and sleep diagnostic/treatment services. The core portfolio centers on the Vivos CARE (Complete Airway Repositioning and Expansion) appliance family — DNA, mRNA, and mmRNA — which are the only oral appliances with FDA 510(k) clearance to treat severe OSA in adults (K230947) and the first cleared for moderate-to-severe pediatric OSA ages 6-17 (K234089). This device platform is complemented by diagnostic tools (VivoScore home sleep testing ring, Airway Intelligence Service for 3D scan analysis) and a progress tracking platform (AireO2). Following a 2025 strategic pivot, the company expanded into sleep center operations by acquiring The Sleep Center of Nevada (7 locations, ~3,000 new patients/month), and launched affiliated center affiliations (MISleep Solutions in Michigan, AIM Florida with South Palm Cardiovascular Associates). Vivos also distributes SoundHealth's Sonu Band and Spatial Sleep Band as a reseller. Revenue streams span appliance/enrollment sales, diagnostic sleep testing services, and treatment center operations.

Differentiator

Problem solved

Functional benefit

Brands

• Vivos CARE: Complete Airway Repositioning and Expansion oral medical devices for treating obstructive sleep apnea, including DNA, mRNA, and mmRNA appliances
• Vivos Method
• VivoScore
• Airway Intelligence Service
• AireO2
• Billing Intelligence Service

Products and services

• Vivos CARE Oral Appliances (DNA, mRNA, mmRNA) FDA 510(k)-cleared line of oral medical devices designed to rehabilitate and restore proper form and function to the airway for treatment of obstructive sleep apnea. The appliances are the only oral appliances with FDA clearance for severe OSA in adults, and the DNA variant is the only one cleared for moderate-to-severe OSA in children ages 6-17.
• DNA Appliance (Daytime-Nighttime Appliance) Custom-made oral appliance FDA-cleared to treat mild-to-severe OSA in adults and moderate-to-severe OSA in children ages 6-17. Typically worn 12-16 hours per day (evening plus sleep). The only oral device FDA-cleared for moderate-to-severe pediatric OSA.
• VivoScore Home Sleep Testing Home sleep testing technology using a small ring sensor worn on the finger during sleep to measure autonomic nervous system responses and provide accurate data about sleep quality and breathing patterns. Results are reviewed by a board-certified sleep physician for diagnosis, with no hospital visit required.
• Airway Intelligence Service Advanced computer analysis service combined with clinical expert review that studies a patient's 3D digital scan of the mouth and recommends which Vivos appliance (DNA, mRNA, or mmRNA) will work best along with the optimal treatment protocol for the patient's unique anatomy.
• AireO2 Patient Progress Tracking Platform Secure online platform where providers track patient treatment progress, enabling adjustments and ensuring treatment stays on track for the 9-12 month Vivos treatment plan.
• The Sleep Center of Nevada (SCN) Diagnostic and Treatment Services Sleep diagnostic and treatment services operated through seven locations across the Las Vegas metropolitan area, providing overnight polysomnogram (PSG) testing, consultation, and treatment delivery for OSA, insomnia, and restless leg syndrome.
• SoundHealth Sonu Band FDA-cleared AI-enabled wearable using personalized vibro-acoustic neuromodulation to treat nasal congestion due to allergic and non-allergic rhinitis, clinically proven on par with intranasal steroids. Uses smartphone front-facing camera to construct personalized anatomical model. Distributed by Vivos through its provider network.
• SoundHealth Spatial Sleep Band FDA-cleared wearable using personalized acoustic resonance therapy with active neural entrainment to promote rapid sleep onset and deeper, longer periods of sleep. Distributed by Vivos through its network of providers.

Quantifiable outcome

• Up to 34% complete resolution (AHI<5) in adult patients treated with Vivos CARE devices
• +4 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered core.

• South Palm Cardiovascular Associates, LLC (SPCVA)coreStrategic or Co-development Partner · 10 June 2026Collaboration agreement forming AIM Florida, LLC to address cardiovascular patients suffering from OSA and insomnia. SPCVA brings approximately 30,000 patients. Vivos holds not less than 80% membership interest. Initial operating plan projects one Sleep Optimization Team could generate over $6 million annually with 50% contribution margins. Model designed for replication across 2,500 similar cardiology groups nationwide.
• SoundHealthcoreTechnology or Integration · 5 February 2026Distribution collaboration for SoundHealth's FDA-cleared Sonu Band and Spatial Sleep Band products. Vivos acts as reseller across its network of over 2,000 trained providers. Partnership includes access to SoundHealth's smartphone-based facial scanning and voice biomarker technology for screening and monitoring sleep disorders. Initial reports indicate high patient satisfaction.
• MISleep Solutions, LLCcoreStrategic or Co-development Partner · 1 July 2025Management services agreement for Auburn Hills, Michigan sleep center. Vivos built out and equipped the center, hired and trained providers, and owns majority equity stake in the management services organization. This capital-efficient affiliation model allows expansion without full acquisition. Grand opening announced December 2025.
• The Sleep Center of Nevada (SCN)coreStrategic or Co-development Partner · 10 June 2025Vivos acquired the operating assets of SCN, the largest operator of medical sleep centers in Nevada with seven locations and nearly 50 beds. SCN sees approximately 3,000 new patients monthly. Vivos paid $6 million cash and $1.5 million in stock, with potential additional $1.5 million stock if financial milestones achieved. This acquisition completed Vivos' pivot from dental provider model to direct medical practice affiliation.

Scale indicators10 records

Recent moves7 records

Expansion highlights7 records

Broad incumbents

• ResMed: Global CPAP market leader and dominant OSA treatment incumbent. Represents the primary treatment alternative Vivos positions against, with broad payer coverage and consumer brand recognition.
• Philips Respironics: Major CPAP and sleep-disordered breathing device manufacturer with a broad respiratory care portfolio. Competes with Vivos as the dominant incumbent in OSA treatment via CPAP and bilevel devices.
• Fisher & Paykel Healthcare: New Zealand-based respiratory care leader with CPAP and nasal mask products for OSA. A broad incumbent in OSA treatment that competes with Vivos from the CPAP side of the market.

Direct peers

• Inspire Medical Systems: Direct competitor in OSA treatment with the Inspire hypoglossal nerve stimulation implant, the leading FDA-approved surgical alternative to CPAP for moderate-to-severe OSA. Targets the same patient population that Vivos addresses with its oral appliances.
• ProSomnus Sleep Technologies: Public peer (OSA) that designs and manufactures custom precision oral appliance therapy devices for OSA. Competes directly with Vivos CARE in the oral appliance category with similar mechanics and patient indications.
• SomnoMed: Global leader in mandibular advancement devices for OSA, with a comparable product portfolio (SomnoDent, Herbst Advance) and a dental provider distribution model. Directly competes with Vivos in the oral appliance category.

Emerging players

• Nyxoah: Belgian developer of the Genio hypoglossal nerve stimulation system for OSA, with a smaller commercial footprint than Inspire but the same therapy modality. Competes with Vivos for severe-to-moderate OSA patients seeking non-CPAP alternatives.
• Apnimed: Clinical-stage pharmaceutical company developing AD109 (a combination of aroxybutynin and atomoxetine) as the first oral medication for OSA. Represents an emerging non-device alternative to CPAP and oral appliances like Vivos CARE.
• Oventus Medical: Australia-based developer of oral appliance therapy for OSA, including the O2Vent product line. Direct partial competitor in the oral appliance category with adjacent geographic footprint.

Others

• Itamar Medical: WatchPAT and Sleep diagnostic technology provider, now part of ZOLL Itamar. Provides home sleep testing devices competitive with Vivos' VivoScore platform and operates in the adjacent OSA diagnostic ecosystem.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/vivos-therapeutics
• Xx.com/vivoslife

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Subsidiaries2 records

Funding overview

Funding rounds9 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vivos Therapeutics